Findings from a multi-center clinical trial of patients undergoing surgery for gynecologic cancer showed that oral apixaban was easier and less painful to administer than subcutaneous enoxaparin (JAMA Netw Open. 2020;3[6]:e207410).
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045